| Title |
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, November 2014
|
| DOI | 10.1007/s00280-014-2615-5 |
| Pubmed ID | |
| Authors |
Anthony W. Tolcher, Amita Patnaik, Kyriakos P. Papadopoulos, Drew W. Rasco, Carlos R. Becerra, Alicia J. Allred, Keith Orford, Gursel Aktan, Geraldine Ferron-Brady, Nageatte Ibrahim, Jennifer Gauvin, Monica Motwani, Mark Cornfeld |
| Abstract |
To identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Saudi Arabia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Netherlands | 1 | <1% |
| Unknown | 102 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 20% |
| Student > Ph. D. Student | 19 | 18% |
| Student > Bachelor | 10 | 10% |
| Student > Master | 10 | 10% |
| Other | 9 | 9% |
| Other | 16 | 15% |
| Unknown | 19 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 30% |
| Biochemistry, Genetics and Molecular Biology | 19 | 18% |
| Agricultural and Biological Sciences | 13 | 13% |
| Nursing and Health Professions | 4 | 4% |
| Sports and Recreations | 2 | 2% |
| Other | 9 | 9% |
| Unknown | 26 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2015.
All research outputs
#19,221,261
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#2,044
of 2,501 outputs
Outputs of similar age
#267,498
of 366,146 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#19
of 26 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 366,146 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.